111 citations
,
August 2002 in “Journal of Medicinal Chemistry” New compounds were made that block an enzyme linked to breast cancer better than existing treatments.
11 citations
,
August 2016 in “Journal of dermatological treatment” Tip cryotherapy effectively treats idiopathic guttate hypomelanosis with minimal side effects.
75 citations
,
June 2007 in “Journal of Biological Chemistry” MT-DADMe-ImmA can selectively kill head and neck cancer cells without harming normal cells.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
70 citations
,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
October 2020 in “Der Hautarzt” Tofacitinib helped regrow hair in a woman with alopecia areata.
1 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
June 2024 in “International Journal of Dermatology” Upadacitinib may effectively treat resistant lichen planopilaris.
August 2020 in “Ugeskrift for Læger” A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.
18 citations
,
January 2013 in “Evidence-based Complementary and Alternative Medicine” Aconiti Lateralis Preparata Radix helps mouse stem cells grow and turn into bone cells faster than usual methods.
May 2025 in “International Journal of Trichology” Baricitinib may effectively treat sudden hair whitening and regrowth in some cases.
7 citations
,
November 2023 in “JAAD Case Reports” Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.
1 citations
,
August 2022 in “JAAD case reports” Tofacitinib and oral minoxidil may help treat Sisaipho alopecia areata.
December 2025 in “Drug Design Development and Therapy” Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.
153 citations
,
November 2004 in “Current Medicinal Chemistry” The document concludes that Catalyst software is effective for drug design, identifying potent compounds for various medical conditions.
June 2026 in “Frontiers in Immunology” Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.
January 2025 in “International Journal of Dermatology” Tofacitinib improved hair and nail conditions in a teen with alopecia areata.
8 citations
,
August 2022 in “Pharmaceutics” Erythrocyte-anchored nanoparticles improved Cepharanthine delivery and effectiveness for treating acute lung injury.
1 citations
,
October 2023 in “Life science alliance” Pantethine may boost the immune system's ability to fight sarcoma.
January 2023 in “Cutaneous and Ocular Toxicology” 68 citations
,
April 2012 in “Digestive and Liver Disease” Elental is a good long-term treatment for Crohn's disease, similar to 6-mercaptopurine but with fewer side effects.
Baricitinib effectively regrows hair in severe alopecia areata cases.
48 citations
,
January 2011 in “International journal of trichology” Intralesional triamcinolone acetonide is the most effective treatment for localized alopecia areata.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” The document discusses the submission of a New Drug Application (NDA) to the U.S. FDA for vepdegestrant (ARV-471), a PROTAC protein degrader targeting the estrogen receptor, by Arvinas and Pfizer. This submission is based on positive results from the Phase 3 VERITAC-2 trial and marks a significant milestone as vepdegestrant is anticipated to be the first FDA-approved PROTAC degrader. PROTACs, a novel class of molecules, selectively degrade disease-causing proteins and offer advantages over traditional small molecule inhibitors, such as mitigating off-target effects and overcoming drug resistance. Despite concerns about their large molecular weight and drug-like properties, recent clinical results have been promising. The success of PROTACs has inspired the development of other chimeric molecules for therapeutic applications.
January 2012 in “Chinese Clinical Oncology” Disodium folinate can safely and effectively replace calcium folinate in colorectal cancer treatment.
1 citations
,
May 2025 in “Frontiers in Medicine” Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.
148 citations
,
March 2022 in “The New England Journal of Medicine” Baricitinib was effective in treating alopecia areata in two major trials.